BOARD CERTIFICATIONS
PROFESSIONAL ASSOCIATIONS
European Society of Medical Oncology
Florida Medical Association
Florida Society of Clinical Oncology
American Society of Clinical Oncology
American Society of Hematology
American Medical Association
American College of Physicians
FELLOWSHIP
State University of New York Downstate Medical Center
Hematology/Oncology
RESIDENCY
Interfaith Medical Center
INTERNSHIP
Tehran University Hospitals
EDUCATION
University of Tehran, School of Medicine
Doctor of Medicine
COMMITTEES
2007- Present
Phase I Cancer Research Program, ICON-FOA, Director
2006- Present
FLASCO Ad hoc Committee on Clinical Trial Network
2002- Present
Research Committee in Cancer Specialists of North Florida, Member
2006
FLASCO Clinical Practice Committee , Member
2004- 2005
Infection Control Committee Putnam Community Medical Center, Chair
2004- 2005
Clinical Quality Council Putnam Community Medical Center, Member
2002-2003
Medical Performance Improvement Committee, Putnam Community Medical Center, Member
2002-2003
CCU/ICU Committee Putnam Community Medical Center, Member
2004
Millennium Oncology Consultant Meeting-Velcade and Multiple Myeloma
2003
Astra Zeneca Advisory Committee - Hormone Therapy for Breast Cancer
2002
Internet Advisory Committee, Zometa for Treatment of Multiple Myeloma and Metastatic Bone Disease. Novartis. Conducted by Dr. James Berenson.
2002
Advisory Committee - Targeted Therapy, New Approach to Cancer Medicine. Novartis
2002
Advisory Committee, Neumega – Thrombocytopenia in Chemotherapy Patients. Wyeth Oncology.
RESEARCH (Principal Investigator Responsibilities)
NCT: N/A
A randomized, multicenter, open-label Study of VELCADE with Rituximab or Rituximab alone in subjects with relapsed or refractory follicular Non-Hodgkin's B-cell lymphoma. Phase III, Interventional
NCT00076024
AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer. Phase I/II, Interventional
NCT00094107
Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma. Phase II, Interventional
NCT00103506
Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma. Phase III, Interventional
NCT00369070
A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC. Phase II, Interventional
NCT00418938
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial. Phase II, Interventional
NCT00451178
An Study of Patients With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Patients Who Take R-CHOP Only. Phase II, Interventional
NCT00609622
Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer. Phase II, Interventional
NCT00695396
A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion. Phase III, Interventional
NCT00858364
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy. Phase III, Interventional
NCT01077154
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE). Phase III, Interventional
NCT01232556
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy. Phase III, Interventional
NCT01254630
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011). Phase III, Interventional
NCT01345019
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma Phase III, Interventional
NCT01740427
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2). Phase III, Interventional
NCT02106546
Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer. Phase III, Interventional
NCT02195479
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma. Phase III, Interventional
NCT02453282
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). Phase III, Interventional
PUBLICATIONS
Blood Journal
Incidence, Clinical Profile and Outcome of Patients with Deep Vein Thrombosis and Pulmonary Embolism at a Community Hospital
Blood Journal
Efficacy and Safety of Ofatumumab and Bendamustine Followed By Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma after Prior Rituximab
Journal of Clinical Oncology
Replacement of ixazomib for relapsed/refractory multiple myeloma patients refractory to a bortezomib or carfilzomib-containing combination therapy.
Journal of Clinical Oncology
Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study
Blood Journal
A Retrospective Study to Evaluate the Incidence and Severity of Peripheral Neuropathy for Relapsed/Refractory Multiple Myeloma Patients upon Retreatment with Bortezomib
Blood Journal
A Retrospective Study to Evaluate the Incidence and Severity of Peripheral Neuropathy for Relapsed/Refractory Multiple Myeloma Patients upon Retreatment with Bortezomib
Blood Journal
A New Multinational Observational Study in Multiple Myeloma: Initial Report of the PREAMBLE Study
Lung Cancer
A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoxlax (Ob) in extensive-stage small cell lung cancer (ES-SCLC).
Journal of Clinical Oncology
Optimizing obatoclax administration schedule: Safety and efficacy of 3-hour versus 24-hour infusion in combination with carboplatin and etoposide for patients with extensive-stage small cell lung cancer.
Journal of Clinical Oncology
A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC).